Acetaminophen: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
MDElliottMD (talk | contribs) Acetaminophen safety depth (launch gate): Overdose+toxicity (Rumack-Matthew nomogram, NAC regimens) + Combination products/325mg FDA cap sections; template byte-preserved; multi-review-passed + mark-greenlit |
||
| Line 18: | Line 18: | ||
| mechanism = <vote slug="apap-mech-claim">Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.</vote> The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. '''Dose-dependent hepatotoxicity''' via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose<ref name="tylenol-label" />. | | mechanism = <vote slug="apap-mech-claim">Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.</vote> The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. '''Dose-dependent hepatotoxicity''' via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose<ref name="tylenol-label" />. | ||
}} | }} | ||
== Overdose and toxicity == | |||
For a single acute ingestion at a known time, the Rumack-Matthew nomogram guides | |||
whether to treat: a serum acetaminophen concentration is drawn no earlier than 4 hours | |||
after ingestion and plotted against time.<ref>Rumack BH, Matthew H. Acetaminophen | |||
poisoning and toxicity. Pediatrics. 1975;55(6):871-876.</ref> In the United States the | |||
treatment line begins at 150 micrograms/mL at 4 hours (set 25% below Rumack and Matthew's | |||
original 200 micrograms/mL line, the FDA-adopted treatment threshold); a level on or above the line | |||
indicates N-acetylcysteine, a level below it does not.<ref>Wallace CI, Dargan PI, Jones | |||
AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J. | |||
2002;19(3):202-205.</ref> The nomogram does NOT apply to chronic or repeated | |||
(staggered) ingestion, an unknown ingestion time, levels drawn before 4 hours, or | |||
modified/extended-release products; in those situations N-acetylcysteine is given | |||
empirically with serial transaminase and acetaminophen monitoring. | |||
Two established N-acetylcysteine regimens are used. The intravenous 21-hour (Prescott) | |||
regimen gives 150 mg/kg as a loading dose, then 50 mg/kg over the next 4 hours, then | |||
100 mg/kg over the following 16 hours.<ref>Prescott LF, Illingworth RN, Critchley JA, et | |||
al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br | |||
Med J. 1979;2(6198):1097-1100.</ref> The oral 72-hour regimen gives a 140 mg/kg loading | |||
dose, then 70 mg/kg every 4 hours for 17 doses.<ref>Smilkstein MJ, Knapp GL, Kulig KW, | |||
Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. | |||
N Engl J Med. 1988;319(24):1557-1562.</ref> Treatment is most effective when started | |||
within 8 hours of ingestion, but is still given later, and in established liver injury or | |||
acute liver failure, where it improves outcomes. Massive or late-presenting overdose may | |||
require extended or increased dosing. This is reference information, not a treatment | |||
protocol; overdose is a medical emergency managed by clinicians and poison control. | |||
== Combination products and the 325 mg limit == | |||
Because acetaminophen is present in many products at once -- prescription opioid | |||
combinations (e.g. hydrocodone/acetaminophen, oxycodone/acetaminophen) and over-the- | |||
counter cold, flu, and sleep products -- people can exceed the maximum daily dose without | |||
realizing it by stacking several acetaminophen-containing products, a leading route to | |||
unintentional hepatotoxicity. In January 2011 the FDA acted on this risk for PRESCRIPTION | |||
acetaminophen products: it asked manufacturers to limit acetaminophen to 325 mg per dosage | |||
unit in prescription combination products (a change manufacturers completed by 2014), and it | |||
required a boxed warning on all prescription products containing acetaminophen highlighting | |||
the potential for severe liver injury.<ref>U.S. Food and Drug Administration. Drug Safety | |||
Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; | |||
boxed warning will highlight potential for severe liver failure. January 13, 2011.</ref> | |||
Over-the-counter acetaminophen products instead carry a Drug Facts "Liver warning," not a | |||
boxed warning. Checking every product label for acetaminophen (sometimes abbreviated APAP) | |||
and summing the total is the practical safeguard. | |||
== References == | == References == | ||
Latest revision as of 07:34, 15 June 2026
Experience
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Overdose and toxicity
For a single acute ingestion at a known time, the Rumack-Matthew nomogram guides whether to treat: a serum acetaminophen concentration is drawn no earlier than 4 hours after ingestion and plotted against time.[2] In the United States the treatment line begins at 150 micrograms/mL at 4 hours (set 25% below Rumack and Matthew's original 200 micrograms/mL line, the FDA-adopted treatment threshold); a level on or above the line indicates N-acetylcysteine, a level below it does not.[3] The nomogram does NOT apply to chronic or repeated (staggered) ingestion, an unknown ingestion time, levels drawn before 4 hours, or modified/extended-release products; in those situations N-acetylcysteine is given empirically with serial transaminase and acetaminophen monitoring.
Two established N-acetylcysteine regimens are used. The intravenous 21-hour (Prescott) regimen gives 150 mg/kg as a loading dose, then 50 mg/kg over the next 4 hours, then 100 mg/kg over the following 16 hours.[4] The oral 72-hour regimen gives a 140 mg/kg loading dose, then 70 mg/kg every 4 hours for 17 doses.[5] Treatment is most effective when started within 8 hours of ingestion, but is still given later, and in established liver injury or acute liver failure, where it improves outcomes. Massive or late-presenting overdose may require extended or increased dosing. This is reference information, not a treatment protocol; overdose is a medical emergency managed by clinicians and poison control.
Combination products and the 325 mg limit
Because acetaminophen is present in many products at once -- prescription opioid combinations (e.g. hydrocodone/acetaminophen, oxycodone/acetaminophen) and over-the- counter cold, flu, and sleep products -- people can exceed the maximum daily dose without realizing it by stacking several acetaminophen-containing products, a leading route to unintentional hepatotoxicity. In January 2011 the FDA acted on this risk for PRESCRIPTION acetaminophen products: it asked manufacturers to limit acetaminophen to 325 mg per dosage unit in prescription combination products (a change manufacturers completed by 2014), and it required a boxed warning on all prescription products containing acetaminophen highlighting the potential for severe liver injury.[6] Over-the-counter acetaminophen products instead carry a Drug Facts "Liver warning," not a boxed warning. Checking every product label for acetaminophen (sometimes abbreviated APAP) and summing the total is the practical safeguard.
References
- ↑ 1.0 1.1 1.2 FDA OTC Monograph for acetaminophen-containing products, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021450s015lbl.pdf
- ↑ Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55(6):871-876.
- ↑ Wallace CI, Dargan PI, Jones AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J. 2002;19(3):202-205.
- ↑ Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br Med J. 1979;2(6198):1097-1100.
- ↑ Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N Engl J Med. 1988;319(24):1557-1562.
- ↑ U.S. Food and Drug Administration. Drug Safety Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit; boxed warning will highlight potential for severe liver failure. January 13, 2011.